Hepion Pharmaceuticals
HEPA
HEPA was delisted on the 12th of May, 2025.
4 hedge funds and large institutions have $1.3M invested in Hepion Pharmaceuticals in 2018 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, reducing their positions, and 1 closing their positions.
20% less funds holding
Funds holding: 5 → 4 (-1)
48% less capital invested
Capital invested by funds: $2.49M → $1.3M (-$1.19M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AFM
Anson Funds Management
Dallas,
Texas
|
-$446K |
| 2 |
PIA
Phoenix Investment Adviser
New York
|
-$36K |
| 3 |
CC
Cornerstone Capital
Palo Alto,
California
|
-$10K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$8K |
| 5 |
ISL
Ingalls & Snyder LLC
New York
|
-$5K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
FFA
26
First Foundation Advisors
Irvine,
California
| – | -$4K | – | – |
|
|
ISL
27
Ingalls & Snyder LLC
New York
| – | -$5K | – | – |
|
|
PIA
28
Phoenix Investment Adviser
New York
| – | -$36K | – | – |
|
|
29
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$8K | – | – |
|
HEPA Hedge Fund Activity: Q1 2018 in Review
4 of the 4,364 institutional investors tracked by Wall St. Rank reported a position in Hepion Pharmaceuticals (HEPA) for Q1 2018, worth a combined $1.3M — down 48% from $2.49M a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of HEPA and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.
The largest seller was Anson Funds Management, exiting entirely with an estimated $446K sold.
- 4 institutional investors held Hepion Pharmaceuticals (HEPA) as of Q1 2018, down from 5 in Q4 2017.
- Funds reported $1.3M of Hepion Pharmaceuticals stock for Q1 2018, down 48% quarter-over-quarter.
- 0 funds opened new Hepion Pharmaceuticals positions in Q1 2018 and 1 closed out, a net change of -1 holder.
- The largest Hepion Pharmaceuticals seller in Q1 2018 was Anson Funds Management, an estimated $446K sold.
Based on aggregated 13F filings for Q1 2018.